Gens & Associates Announce Premier Benchmark Membership Program
WASHINGTON CROSSING, Pa., September 16, 2019 /PRNewswire-PRWeb/ -- Gens & Associates today announced the launch of their Benchmark Premier Membership. The program gives members access to the latest and most respected Regulatory Information Management (RIM) benchmarking data and access to global expertise.
The program is designed to expand the company's research platform while providing customized actionable guidance to help organizations tackle the complexities of regulatory cost pressures, evolving e-submissions standards, global workflows and automated connections to other functional assets such as enterprise resource planning (ERP) systems.
Benchmark Premier extends the existing Gens & Associates RIM Benchmark, a biennial research survey that provides the industry's most comprehensive independent regulatory benchmarking data. Participants in the Benchmark survey include more than 100 global biopharmaceutical, medical device, consumer and generic drug companies and the providers that support them, as well as more than 1,000 regulatory and business professionals.
The expansion of Gens' research comes at a crucial time for the industry.The industry is undergoing change in global government submission requirements and is challenged by IT system silos and process inefficiencies. Life sciences organizations increasingly recognize the importance of RIM as an enterprise capability that impacts compliance, productivity and time to market. To advance their RIM capabilities and achieve strong performance or World Class RIM status, businesses depend on accurate insights into regulatory trends and actionable performance guidance from the Benchmark survey's unbiased data.
"We're excited about our new Benchmark Premier program, which enables us to share greater and deeper insights from our rapidly expanding Benchmark research data," said Steve Gens, managing director and co-founder of the biennial RIM surveys. "We are extending into new sectors to reach more life sciences organizations of all sizes and product types - drug, biotech, generic, animal health, medical device and agricultural. We'll continue our work on World Class RIM and further concentrate our research with cross-functional connection points to commercial, clinical, PV/safety, and Medical Affairs along with structured data submissions to health authorities. Our expert team is at the forefront of delivering independent and trusted RIM Benchmark data that measure world-class RIM, prioritize investments, and help businesses avoid expensive projects that won't move the performance dial."
Participants in both the Gens Benchmark and Benchmark Premier Program have access to no-cost biennial benchmark survey results and community debrief sessions. Benchmark Premier members receive additional services, including on-site annual private working sessions to improve company performance and refine regulatory roadmaps, interim research on hot topics, access to private events and content, and the ability to tap into the Gens & Associates' network of experts. Members of either tier can switch to the other program at defined points, to align with their organization's strategic planning cycles.
The two Benchmark programs also benefit service and software providers, who rely on the Benchmark data for accurate insights into where the industry is heading, economic analysis for the total addressable market they serve, and how to align their products and services to project where their clients will be in two to three years.
About Gens & Associates
A boutique Life Science management and organizational consultancy specializing in strategic planning and roadmap development, industry benchmarking, regulatory information management, organizational transition management, and working with leadership and project teams to accelerate change and value realization.
Their mission is to help all stakeholders in the regulatory eco-system accelerate global transformation, increase efficiency and organizational agility to shorten approvals of effective new drugs and contribute to medicine affordability. We do this through strategic leadership, enhancing industry standards, collaboration and deep insights derived from our recognized research platform that bring precision to identify the most effective changes and outcomes.
SOURCE Gens & Associates
